Supplemental Online Content

Low EV, Tok PSK, Husin M, et al. Assessment of heterologous and homologous boosting with inactivated COVID-19 vaccine at 3 months compared with homologous boosting of BNT162b2 at 6 Months. JAMA Netw Open. 2022;5(8):e2226046. doi:10.1001/jamanetworkopen.2022.26046

eTable 1. Subgroup Analysis With Primary Vaccination Series as the Reference Group
eTable 2. Unadjusted and Adjusted Odds Ratios for Risk of Symptomatic SARS-CoV-2 Infection Using 7 Days After Third Dose as Fully Boosted

This supplemental material has been provided by the authors to give readers additional information about their work.
**eTable 1: Subgroup Analysis using primary vaccination series as reference group**

| Type of Vaccines Combination | Adjusted OR (95% CI)* |
|------------------------------|-----------------------|
| BNT162b2 as Primary series   |                       |
| 3 Doses of BNT162b2 vs. 2 doses of BNT162b2 | 0.01 (0.00, 0.01) |
| CoronaVac as Primary series  |                       |
| 2 Doses CoronaVac + BNT162b2 vs. 2 doses of CoronaVac | 0.03 (0.03, 0.04) |
| 3 Doses of CoronaVac vs. 2 dose of CoronaVac | 0.04 (0.03, 0.05) |

*Adjusted for age, ethnicities, sex, state, health care worker status, baseline exposure risk (trace), month of full vaccination, procurement mechanism, and presence of comorbidities
### eTable 2: Unadjusted and Adjusted Odds Ratio Against Symptomatic SARS-CoV-2 Infection using fully booster as 7 days after third dose

| Type of Vaccines Combination* | Full cohort | 18 to 39 years old | 40 to 59 years old | 60 years old and above |
|------------------------------|-------------|--------------------|-------------------|-----------------------|
|                              | OR (95% CI) | Adjusted OR (95% CI)* | Adjusted OR (95% CI)* | Adjusted OR (95% CI)* |
| 2 Doses of CoronaVac vs. 2 Doses of BNT162b2 | 1.55 (1.53, 1.57) | 1.76 (1.71, 1.82) | 1.76 (1.69, 1.82) | 1.93 (1.80, 2.06) | 3.66 (3.66, 3.67) |
| 3 doses of BNT162b2 vs. 2 doses of BNT162b2 | 0.01 (0.01, 0.01) | 0.01 (0.01, 0.02) | 0.02 (0.01, 0.03) | 0.01 (0.00, 0.01) | 0.15 (0.15, 0.15) |
| 2 Doses CoronaVac + BNT162b2 vs. 2 doses of BNT162b2 | 0.11 (0.11, 0.12) | 0.10 (0.09, 0.11) | 0.09 (0.08, 0.10) | 0.12 (0.11, 0.13) | 0.20 (0.20, 0.20) |
| 3 Doses of CoronaVac vs. 2 dose of BNT162b2 | 0.13 (0.12, 0.14) | 0.15 (0.13, 0.18) | 0.17 (0.14, 0.22) | 0.15 (0.12, 0.20) | 0.24 (0.23, 0.24) |

*Adjusted for age, ethnicities, sex, state, baseline exposure risk (trace), frontlineer status, month of full vaccination, procurement mechanism, and presence of comorbidities